Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
作者信息
Trujillo Jonathan A, Godfrey James, Hu Yifei, Huang Jun, Smith Sonali M, Frigault Matthew J, DeFilipp Zachariah, Appelbaum Daniel, Pu Yonglin, Feinberg Nicholas, Althaus Thomas, Bishop Michael R, Riedell Peter A, Kline Justin
机构信息
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
出版信息
Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
Abstract
摘要
相似文献
1
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
2
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Haematologica. 2021 Jan 1;106(1):255-258. doi: 10.3324/haematol.2019.243246.
3
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.
Blood Adv. 2024 Oct 22;8(20):5290-5296. doi: 10.1182/bloodadvances.2024013863.
4
Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.
Bone Marrow Transplant. 2020 Jun;55(6):1184-1187. doi: 10.1038/s41409-019-0657-3. Epub 2019 Aug 30.
5
[Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):788-792. doi: 10.3760/cma.j.issn.0253-2727.2022.09.014.
6
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
Leuk Lymphoma. 2024 Mar;65(3):389-393. doi: 10.1080/10428194.2023.2285236. Epub 2023 Nov 30.
7
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.
Haematologica. 2023 Jan 1;108(1):290-294. doi: 10.3324/haematol.2022.281351.
8
Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.
Bone Marrow Transplant. 2021 Mar;56(3):679-682. doi: 10.1038/s41409-020-01018-7. Epub 2020 Aug 6.
9
Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma.
Nat Med. 2022 Dec;28(12):2458-2459. doi: 10.1038/s41591-022-02067-9.
10
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Haematologica. 2023 Dec 1;108(12):3433-3437. doi: 10.3324/haematol.2022.282345.
引用本文的文献
1
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.
Hemasphere. 2025 Feb 18;9(2):e70091. doi: 10.1002/hem3.70091. eCollection 2025 Feb.
2
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study.
Hemasphere. 2025 Feb 4;9(2):e70077. doi: 10.1002/hem3.70077. eCollection 2025 Feb.
3
High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role?
Cells. 2024 Oct 27;13(21):1780. doi: 10.3390/cells13211780.
4
Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
Immunotherapy. 2024;16(18-19):1105-1111. doi: 10.1080/1750743X.2024.2409622. Epub 2024 Oct 17.
5
CARs to the rescue: rare aggressive lymphoma gets a power up.
Blood Adv. 2024 Oct 22;8(20):5342-5343. doi: 10.1182/bloodadvances.2024014118.
6
Immune checkpoint blockade and CAR T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma: Challenges and opportunities.
Heliyon. 2024 Sep 18;10(18):e38023. doi: 10.1016/j.heliyon.2024.e38023. eCollection 2024 Sep 30.
7
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.
Blood Adv. 2024 Nov 12;8(21):5571-5578. doi: 10.1182/bloodadvances.2024013152.
8
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.
Blood Adv. 2024 Oct 22;8(20):5290-5296. doi: 10.1182/bloodadvances.2024013863.
9
CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers.
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):357-363. doi: 10.1182/hematology.2023000436.
10
[Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2023 Oct 14;44(10):820-824. doi: 10.3760/cma.j.issn.0253-2727.2023.10.005.
本文引用的文献
1
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Blood. 2021 Mar 11;137(10):1353-1364. doi: 10.1182/blood.2020006464.
2
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.
Blood Adv. 2020 Jul 28;4(14):3268-3276. doi: 10.1182/bloodadvances.2020001900.
3
The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
Blood. 2020 Feb 20;135(8):523-533. doi: 10.1182/blood.2019000847.
4
Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.
Leuk Lymphoma. 2019 Dec;60(14):3426-3433. doi: 10.1080/10428194.2019.1639166. Epub 2019 Jul 9.
5
gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
Blood. 2019 May 23;133(21):2279-2290. doi: 10.1182/blood-2018-10-879015. Epub 2019 Mar 25.
6
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
7
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
8
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
9
, , , and are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.
Haematologica. 2019 Feb;104(2):330-337. doi: 10.3324/haematol.2018.203224. Epub 2018 Sep 13.
10
T-cell/histiocyte-rich large B-cell lymphoma.
Haematologica. 2010 Mar;95(3):352-6. doi: 10.3324/haematol.2009.016931.
Zotero 插件